LUMOXITI MECHANISM OF ACTION
LUMOXITI is the first and only FDA-approved CD22-directed therapy developed for the treatment of adult patients with relapsed/refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA)1
Take a Targeted Approach to Hairy Cell Leukemia Treatment With LUMOXITI
LUMOXITI features PE38 fused to a recombinant murine immunoglobulin variable domain1

Recombinant murine immunoglobulin variable domain
Engineered to bind to CD22 surface antigen on CD22-expressing cells

PE38
A truncated Pseudomonas exotoxin that inhibits protein synthesis
LUMOXITI specifically targets the surface antigen CD22 which is overexpressed in hairy cells1-3

- CD22 is a surface antigen expressed on hairy cells
- LUMOXITI binds CD22 on the surface of CD22-expressing cells
- Once bound, LUMOXITI is internalized
- LUMOXITI internalization results in ADP-ribosylation of elongation factor 2, inhibition of protein synthesis, and apoptotic cell death
LUMOXITI inhibits protein synthesis, resulting in apoptosis1,4
Adapted from Schneider AK et al. J Immunol Methods. 2016;435:68-76.4